Evidence map›Paper›PMID 39772162›Full record

ReviewViruses2024

Isothermal Nucleic Acid Amplification for Point-of-Care Primary Cervical Cancer Screening.

Maryame Lamsisi, Abdelhamid Benlghazi, Jaouad Kouach, Abdelilah Laraqui, Moulay Mustapha Ennaji, Céline Chauleur, Thomas Bourlet, Guorong Li

Abstract readReview
In one paragraph

Review in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maryame LamsisiBiotechnology Unit, Institut Pasteur du Maroc, Casablanca 20360, Morocco.ORCID 0000-0002-7855-6020
Abdelhamid BenlghaziDepartment of Obstetrics & Gynecology, Mohamed V Military Instruction Hospital of Rabat, Rabat 10045, Morocco.
Jaouad KouachDepartment of Obstetrics & Gynecology, Mohamed V Military Instruction Hospital of Rabat, Rabat 10045, Morocco.
Abdelilah LaraquiLaboratory of Virology, Mohamed V Military Instruction Hospital of Rabat, Rabat 10045, Morocco.ORCID 0000-0002-1375-6021
Moulay Mustapha EnnajiLaboratory of Virology, Oncology, Biosciences, Environment, and New Energies, Faculty of Sciences and Techniques Mohammedia, Mohammedia 20650, Morocco.
Céline ChauleurDepartment of Obstetrics & Gynecology, North Hospital, Centre Hospitalier Universitaire Saint Etienne, 42055 Saint Etienne, France.
Thomas BourletLaboratory of Virology, North Hospital, CHU Saint Etienne, 42055 Saint Etienne, France.
Guorong LiDepartment of Urology, North Hospital, CHU Saint Etienne, 42055 Saint Etienne, France.ORCID 0000-0003-4457-3380

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human Papillomavirus (HPV) infection is a significant global health concern linked to various cancers, particularly cervical cancer. Timely and accurate detection of HPV is crucial for effective management and prevention strategies. Traditional laboratory-based HPV testing methods often suffer from limitations such as long turnaround times, restricted accessibility, and the need for trained personnel, especially in resource-limited settings. Consequently, there is a growing demand for point-of-care (POC) HPV testing solutions that offer rapid, easy-to-use, and convenient screening at the primary care level. This review provides a comprehensive overview of recent advancements and emerging technologies utilized in POC HPV testing using isothermal amplification methods, in addition to evaluating their diagnostic performance, sensitivity, specificity, and clinical utility compared to conventional laboratory-based assays, particularly in low-resource settings, where access to centralized laboratory facilities is limited. We provide insights into the potential of isothermal nucleic acid amplification to revolutionize cervical cancer screening and prevention efforts worldwide, with emphasis on the need for continued research, innovation, and collaboration to optimize the performance, accessibility, and affordability of POC HPV testing solutions, ultimately contributing to the worldwide effort towards the elimination of this disease.

Indexed as

Early Detection of CancerMolecular Diagnostic TechniquesNucleic Acid Amplification TechniquesPapillomavirus InfectionsPoint-of-Care SystemsSensitivity and SpecificityUterine Cervical NeoplasmsDNA, ViralFemaleHumansMass ScreeningPapillomaviridaePoint-of-Care TestingDNA, Viralcervical cancer screeningdetectionhuman papillomavirusisothermal nucleic acid amplificationpoint-of-care

Identifiers

PMID39772162
PMCPMC11680343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.